Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy
between this translated document and the Japanese original, the original shall prevail.

August 2, 2024

Consolidated Financial Results
for the Three Months Ended June 30, 2024
(Under Japanese GAAP)
Company name:
Mochida Pharmaceutical Co., Ltd.
Listing:
Tokyo Stock Exchange
Securities code:
4534
URL:
https://www.mochida.co.jp/english/
Representative:(Name) Naoyuki Mochida (Title) Representative Director, President
Inquiries:(Name) Kenichi Miyamoto (Title) Head of Finance & Accounting Department
Telephone:+81-3-3358-7211
Scheduled date to commence dividend payments:
Preparation of supplementary material on financial results:
None
Holding of financial results briefing:
None(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the three months ended June 30, 2024 (from April 1, 2024 to June 30,2024)(1) Consolidated operating results (cumulative)
Net sales
Three months ended(Percentages indicate year-on-year changes.)

Operating profit

Profit attributable toowners of parentOrdinary profit

Millions of yen%

Millions of yen%

Millions of yen%

Millions of yen%

June 30, 2024

25,4072.72,189(13.0)

2,367(8.7)

1,554(7.9)

June 30, 2023

24,747(10.6)

2,515(41.0)

2,592(41.3)

1,688(46.5)

Note: Comprehensive income

For the three months ended June 30, 2024:
For the three months ended June 30, 2023:

Basic earnings per
share

Diluted earnings per
share

Yen

Yen

Three months ended
June 30, 2024

43.85

-

June 30, 2023

46.24-¥848 million¥2,427 million[(65.0)%][(26.2)%](2) Consolidated financial position
Total assets
As ofNet assets

Equity-to-asset ratio

Millions of yen

Millions of yen

June 30, 2024

158,051

127,396

80.6

March 31, 2024

158,800

127,967

80.6

Reference: Equity
As of June 30, 2024:
As of March 31, 2024:¥127,396 million¥127,967 million%

2. Cash dividends
Annual dividends per shareFirst
quarter-end

Secondquarter-end

Yen
Fiscal year ended-

March 31, 2024
Fiscal year ending

Third
quarter-end

Yen

Fiscal year-end

Yen

TotalYen

Yen

40.00

-40.00

80.00

40.00

-40.0080.00-March 31, 2025
Fiscal year ending

March 31, 2025 (Forecast)

Note: Revisions to the forecast of cash dividends most recently announced: None

3. Consolidated financial result forecasts for the fiscal year ending March 31, 2025 (from April 1, 2024 toMarch 31, 2025)(Percentages indicate year-on-year changes.)
Net sales
Millions ofyen

Operating profit%

Millions ofyen

Profit attributable toowners of parent

Ordinary profit%

Millions ofyen

Full year
106,000
3.0
7,500
29.3
7,700
Note: Revisions to the financial result forecast most recently announced: None

Basic earnings
per share%

Millions ofyen%

Yen

27.5

5,600

23.1

157.96* Notes(1) Significant changes in the scope of consolidation during the period: None
Newly included: - companies (Company name)
Excluded:- companies (Company name)(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements:
Yes(3) Changes in accounting policies, changes in accounting estimates, and restatement(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None(ii) Changes in accounting policies due to other reasons: None(iii) Changes in accounting estimates: None(iv) Restatement: None
(4) Number of issued shares (common shares)(i)

Total number of issued shares at the end of the period (including treasury shares)
As of June 30, 2024

37,470,000 shares

As of March 31, 2024

37,470,000 shares(ii) Number of treasury shares at the end of the period
As of June 30, 2024

2,018,759 shares

As of March 31, 2024

2,018,491 shares(iii) Average number of shares outstanding during the period (cumulative)
Three months ended June 30, 2024

35,451,376 shares

Three months ended June 30, 2023

36,511,601 shares* Review of the Japanese-language originals of the attached consolidated quarterly financial statements bycertified public accountants or an audit firm: None
* Explanation of the proper use of financial result forecasts and other special matters
The financial result forecasts presented in this document are based on information that is currently available to
the Company as of the announcement of this document, and the Company does not guarantee to achieve them.
In addition, actual financial results may differ significantly from these forecasts due to a wide range of factors.

Quarterly Consolidated Financial Statements(1) Quarterly Consolidated Balance Sheets(Millions of yen)
As of March 31, 2024
AssetsCurrent assets
Cash and deposits
Accounts receivable - trade
Securities
Merchandise and finished goods
Work in process
Raw materials and supplies
Other
Total current assets
Non-current assets
Property, plant and equipment
Buildings and structures, net
Machinery, equipment and vehicles, netLand
Other, net
Total property, plant and equipment
Intangible assetsInvestments and other assets
Investment securities
Deferred tax assets
Other
Total investments and other assets
Total non-current assets
Total assets

1

As of June 30, 2024

33,29034,83813,49918,535
1,428
10,315
4,753
116,662

36,22632,617
13,49918,395
2,367
10,215
3,432
116,753

6,823
1,667
5,993
1,390
15,874
721

6,746
1,866
5,993
1,341
15,948714

16,116
2,372
7,052
25,541
42,138
158,800

15,1002,748
6,785
24,634
41,297
158,051

(Millions of yen)
As of March 31, 2024
Liabilities
Current liabilities
Notes and accounts payable - trade
Electronically recorded obligations - operating
Income taxes payable
Provision for bonuses
Other provisions
Other
Total current liabilities
Non-current liabilities
Retirement benefit liability
Other
Total non-current liabilities
Total liabilities
Net assets
Shareholders’ equity
Share capital
Capital surplus
Retained earnings
Treasury shares
Total shareholders’ equity
Accumulated other comprehensive income
Valuation difference on available-for-sale securities
Remeasurements of defined benefit plans
Total accumulated other comprehensive income
Total net assets
Total liabilities and net assets

2

As of June 30, 2024

10,975
1,207
593
2,140
163
10,992
26,073

9,840
1,152
928
992
115
12,89425,924

3,908
851
4,759
30,833

3,879
850
4,730
30,6547,229
1,871
117,022(7,021)
119,102

7,229
1,871
117,158(7,021)
119,237

8,585
279
8,864
127,967
158,800

7,897
261
8,158
127,396
158,051

(2) Quarterly Consolidated Statements of Income and Comprehensive Income
Quarterly Consolidated Statements of Income
Three Months Ended June 30(Millions of yen)

Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating profit
Non-operating income
Interest income
Dividend income
Other
Total non-operating income
Non-operating expenses
Interest expenses
Share of loss of entities accounted for using equity
methodCommission expenses
Foreign exchange losses
Other
Total non-operating expenses
Ordinary profit
Extraordinary income
Gain on sale of non-current assets
Settlement income
Total extraordinary income
Extraordinary losses
Loss on sale and retirement of non-current assets
Total extraordinary losses
Profit before income taxes
Income taxes
ProfitProfit attributable to owners of parent

For the three months ended
June 30, 2023
24,747
11,542
13,205
10,6892,515

For the three months ended
June 30, 2024
25,407
12,451
12,955
10,766
2,189

0
181
36
218

0
203
29
234

00

43

24

3
90
3
142
2,592

3
25
2
56
2,367

—
11111
—
131
31
2,572
884
1,688
1,688

4
4
2,364
809
1,554
1,554

3

Quarterly Consolidated Statements of Comprehensive Income
Three Months Ended June 30(Millions of yen)

ProfitOther comprehensive income
Valuation difference on available-for-sale securities
Remeasurements of defined benefit plans, net of tax
Total other comprehensive income
Comprehensive income
Comprehensive income attributable toComprehensive income attributable to owners of parent

For the three months ended
June 30, 2023
1,688

For the three months ended
June 30, 2024
1,554

750
(11)
738
2,427(687)
(18)
(706)
848

2,427

8484

Sales of Major Products（Three months ended June 30, 2024)（Billions of yen）
Products

Fiscal year ended

Fiscal year ending

March 31, 2024

March 31, 2025

Apr-Jun

Apr-MarApr-Jun

Apr-Mar
forecast

Threemonths
Y o Ychanges%Treatment of ulcerative colitis

Lialda®

3.6

14.5

3.7

14.6+ 3%Treatment for chronic constipation

Goofice®

1.9

7.7

2.09.0+ 7%

Drug for hyperlipidemia andarteriosclerosis obliterans

Epadel2.0

7.4

1.56.5△ 25%

Treatment for chronic constipation

Movicol®

1.4

5.9

1.5

6.0

+ 9%

Gout and hyperuricemia

Urece®

0.7

3.3

1.0

5.4

+ 38%

AntidepressantLexapro®

1.3

5.2

0.9

3.7

△ 28%

Treatment for pulmonary arterial
hypertension
Analgesic for chronic pain and pain
after tooth extraction
Calcium channel blocker with a longacting hypotensive effectTreprost®

0.4

2.3

1.02.8+ 134%

Tramcet®

0.6

2.2

0.4

2.0

△ 23%

Atelec®

0.6

2.3

0.4

1.8

△ 24%

Treatment of ulcerative colitis

Cortiment®

-

0.2

0.0

1.4

-

Anticoagulant agent

Heparin Sodium
MOCHIDA

0.3

1.3

0.3

1.2

+ 1%

Therapeutic agent for endometriosis,
adenomyosis and dysmenorrhea

Dinagest

0.2

1.1

0.2

0.7

△ 21%

Generic drugs

7.4

32.6

7.2

28.5

△ 3%Skin Care Products

1.66.4

1.66.8+ 5%

Sales of Atelec® are the sum of Atelec® and Atedio®.
Cortiment® was launched in September 2023.

5Development Pipeline【Ethical drug】
Development code
<Generic name>
ACT-541468<daridorexant>

MD-711<treprostinil>* MD-0901<mesalazine>

FYU-981<dotinurad>* MND-21<icosapent>Stage

Indications

Formulation
OralRemarks<Development country>
Co-development with Nxera Pharma Japan Co., Ltd.
(Former Idorsia Pharmaceuticals Japan Ltd.)<Japan>FiledInsomnia

FiledPulmonary hypertension
associated withLicensed-in from United Therapeutics Corporationinterstitial lung disease or Inhalant In-house development<Japan>combined pulmonary
fibrosis and emphysema

Filed

Ulcerative colitis（pediatric indication）

Oral

Licensed-in from Takeda Pharmaceuticals U.S.A., Inc.
In-house development<Japan>Phase Ⅲ

Gout andhyperuricemia(pediatric indication)

Oral

Co-development with FUJI YAKUHIN Co., Ltd.
<Japan>FiledHypertriglyceridemia

Oral

Collaboration on development with Sumitomo Pharma(Suzhou) Co., Ltd.
<China>【Medical device】
Development code or
Product nameｄMD-001

ｄMD-002

ｄMD-003* ReFeel

Stage

Intended use or indications

Remarks<Development country>

Articular cartilage lesion

In-house development<Japan>Therapeutic
Cavernous nerve injury
exploratory study

In-house development<Japan>Therapeuticconfirmatory
study

Post-operative adhesion

In-house development<Japan>Cleared(510(k))

Peripheral nerve injury

In-house development
<USA>

Filed

Stages of Medical devices are classified into “Therapeutic exploratory study” and “Therapeutic confirmatory study”.

* Updates from May 13, 2024

6